The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 19, 2013

Filed:

Jan. 31, 2006
Applicants:

Bing-hua Jiang, Morgantown, WV (US);

Jing Fang, Shanghai, CN;

Inventors:

Bing-Hua Jiang, Morgantown, WV (US);

Jing Fang, Shanghai, CN;

Assignee:

ACC Therapeutics Inc, Gaithersburg, MD (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A01N 43/00 (2006.01); A01N 43/16 (2006.01);
U.S. Cl.
CPC ...
Abstract

Apigenin is a nontoxic compound. The present invention is appropriate for apigenin use in people who have a high risk of getting cancer, and in people who have cancer through chemoprevention and chemotherapy, respectively. We showed that apigenin inhibited cancer cell proliferation, tumor growth and angiogenesis. Apigenin selectively inhibited proliferation and induced apoptosis of cancer cells, enhanced the sensitivity of different cancer cells to different therapeutic drugs including cisplatin and taxol. Apigenin also inhibits angiogenesis and tumor growth in human cancers, and inhibits angiogenic inducers such as hypoxia-inducible factor 1 (HIF-1) and vascular endothelial growth factor (VEGF). Apigenin inhibited expression of HIF-1 and VEGF through PI3K, AKT, p70S6K1 and HDM2 pathways, which are commonly observed in all kinds of human cancers. Thus, our results indicate that apigenin can be applied to various human cancers for chemoprevention, and for chemotherapy when combined with other therapeutic reagents.


Find Patent Forward Citations

Loading…